Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cassier PA et al. – Gemcitabine-oxaliplatin combination (GEMOX) is active and well tolerated in pretreated pts with metastatic neuroendocrine tumors. Methods- Study of GEMOX efficacy in treatment of pts with metastatic neuroendocrine tumors
- GEMOX treatment for 20 consecutive pts with progressive disease, most cases after failure of other chemotherapy regimens (median 2 regimens)
- Follow-up for evidence of toxicity, response, and survival
- Exclusion from efficacy analysis of 2 pts chemotherapy-naive at treatment initiation
Results- Toxicity manageable overall
- Treatment discontinuation due to oxaliplatin-induced neurotoxicity (grade 2) in 6 pts (30%)
- Partial response for 3 (17%) of 18 pts
- Median progression-free survival: 7 mo
- Median overall survival: 23.4 mo
[more...]
|
|
|
